Volume 16 Supplement 1
P025. Two-year follow-up with OnabotulinumtoxinA for chronic migraine: a real life evaluation of 113 patients
© Santoro et al. 2015
Published: 28 September 2015
To assess the real life efficacy of 155U-195U OnabotulinumtoxinA in CM patients in order to retrospectively investigate the benefits of such treatment and observe if the efficacy is sustained after one year.
We reviewed the charts of 134 patients treated with OnabotulinumtoxinA who received up to 9 cycles. Patients were injected regularly with a 3-month (±10 days) interval. They were assessed for headache days and hours, intensity of pain by Visual Analogue Scale (VAS), number of any acute drug intake. Photophobia, phonophobia, osmophobia, nausea were assessed as well. The results were also analysed based on the CM onset.
Time in months
% of Reduction vs Baseline
24.1 (22.1 - 26.3)
16.4 (14.8 - 18.1)
11.1 (9.7 - 12.7)
7.5 (6.3 - 9.1)
5.1 (4.0 - 6.5)
3.5 (2.6 - 4.7)
2.4 (1.7 - 3.3)
1.6 (1.1 - 2.4)
1.1 (0.7 - 1.7)
Our real life experience demonstrated the efficacy and tolerability of the OnabotulinumtoxinA responders already after the first treatment cycles. Overtime, not only a sustained efficacy was observed but also a favorable trend of improvement with no significant adverse events. Moreover, our analysis confirmed that the efficacy outcomes were not affected by the CM onset thus allowing us to assume that OnabotulinumtoxinA can be considered a valuable first line treatment to allow more patients to benefit earlier and more consistently from this therapeutic option.
Written informed consent to publish was obtained from the patient(s).
- Aurora SK, Winner P, Freeman MC, Spierings EL, Heiring JO, DeGryse RE, et al: OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Analyses of the 56-Week PREEMPT Clinical Program. Headache. 2011, 51 (9): 1358-1373. 10.1111/j.1526-4610.2011.01990.x.View ArticlePubMedGoogle Scholar
- Cernuda-Morollón E, Ramon C, Larrosa D, Alvarez R, Riesco N, Pascual J: Long-term experience with onabotulinumtoxinA in the treatment of chronic migraine: What happens after one year?. Cephalalgia. 2014, 35 (10): 864-868.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.